Markets

Insider Trading

Hedge Funds

Retirement

Opinion

5 Best Pet Care Stocks to Buy for Consistent Recurring Revenue

In this article, we will discuss the 5 Best Pet Care Stocks to Buy for Consistent Recurring Revenue. For deeper discussion and analysis, read 7 Best Pet Care Stocks to Buy for Consistent Recurring Revenue.

5. IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Short Percentage of Shares Outstanding: 2.76% 

On May 26, IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced the expansion of its Fecal Dx antigen testing platform to include detection of taeniid tapeworm species, including Taenia and Echinococcus. The enhanced testing capability is designed to identify a broader range of intestinal parasite infections and has been shown to detect up to twice as many infections earlier than fecal flotation alone. Beginning in late June, IDEXX Reference Laboratories customers across the United States and Canada will automatically receive taeniid tapeworm detection within Fecal Dx antigen testing panels and profiles at no additional cost, further strengthening the value of the company’s diagnostic offerings.

Previously, on May 19, IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced that its SDMA renal biomarker will be integrated into Catalyst CLIPs, making comprehensive kidney function evaluation a standard component of the most used point-of-care chemistry profiles. Available to customers in the United States and Canada beginning in June, the integration is expected to improve access to advanced kidney health assessments and enable veterinarians to identify kidney function decline earlier without changing existing clinical workflows. Since launching the IDEXX SDMA Test in 2015, the company has performed approximately 119 million SDMA tests globally, demonstrating strong adoption and reinforcing the biomarker’s importance in veterinary kidney disease management.

Founded in 1983 and headquartered in Westbrook, Maine, IDEXX Laboratories, Inc. (NASDAQ:IDXX) deals in veterinary diagnostics, software, and water microbiology. It provides veterinarians with advanced in-clinic diagnostic instruments, rapid testing kits, and reference laboratory services that enable them to provide immediate, high-quality medical care to pets.

4. PetMed Express, Inc. (NASDAQ:PETS)

Short Percentage of Shares Outstanding: 2.48% 

On June 2, PetMed Express, Inc. (NASDAQ:PETS) reported fourth-quarter revenue of $42.82 million, compared with $50.76 million in the prior-year period. Despite the year-over-year decline, management highlighted a sequential increase in quarterly net sales, signaling improving business momentum. Interim Chief Executive Officer and President Leslie Campbell stated that throughout 2026, the company focused on stabilizing its core operations and strengthening the foundation for long-term value creation through strategic, operational, and technology initiatives that reduced costs and enhanced efficiency. Management also emphasized plans to improve customer retention, expand business-to-business relationships, and leverage membership programs and white-label pharmacy fulfillment services, including its recently announced Master Services Agreement with Rural King.

On April 22, PetMed Express, Inc. (NASDAQ:PETS) announced a strategic partnership with Rural King to launch a new pet pharmacy platform, broadening access to prescription medications, preventative treatments, and pet healthcare products across Rural King’s retail and digital channels. Under the agreement, PetMeds will provide the pharmacy infrastructure, licensed pharmacists, and e-commerce capabilities required to support the offering. Management noted that the partnership aligns with the company’s growth strategy by extending its pharmacy platform to millions of pet owners who rely on Rural King for farm, ranch, and pet care products, while further advancing its mission of making quality pet healthcare more accessible and affordable nationwide.

Founded in 1996 and headquartered in Delray Beach, Florida, PetMed Express, Inc. (NASDAQ:PETS) is an online pet pharmacy and health retailer. The company markets and delivers FDA and EPA-approved prescription medications, over-the-counter flea and tick treatments, supplements, and specialized foods directly to pet owners nationwide, making it among the best pet care stocks to buy for consistent recurring revenue.

3. Oil-Dri Corporation of America (NYSE:ODC)

Short Percentage of Shares Outstanding: 2.21% 

On June 8, Oil-Dri Corporation of America (NYSE:ODC) reported third-quarter revenue of $126.33 million, compared with $115.5 million in the prior-year period. President and CEO Daniel Jaffee highlighted that, following two quarters of difficult year-over-year comparisons, the company returned to growth with record third quarter consolidated net sales increasing 9%. Combined with disciplined expense management, the sales growth contributed to a 25% increase in net income despite ongoing inflationary pressures on the cost of goods sold. Management also noted that strong cash generation enabled the company to continue returning capital to shareholders and expressed confidence in achieving its annual plan and surpassing the previous year’s net income. However, geopolitical uncertainty and higher transportation and input costs remain potential headwinds.

On June 3, the board of directors of Oil-Dri Corporation of America (NYSE:ODC) approved a two-cent increase in the company’s quarterly cash dividend. The new dividend was raised to $0.225 per share of common stock and $0.168 per share of Class B stock, representing an approximate 10% increase for both share classes. The dividends will be payable on August 21 to shareholders of record as of August 7. In addition, the board authorized the repurchase of up to 500,000 shares of common stock, supplementing the shares already available under previous repurchase authorizations and demonstrating the company’s ongoing commitment to shareholder returns.

Founded in 1941 and headquartered in Chicago, Illinois, the Oil-Dri Corporation of America (NYSE:ODC) is a manufacturer of specialty sorbent products mined from specialty minerals. The company also produces widely used clay- and diatomaceous earth-based cat litter under major consumer brands like Cat’s Pride and Jonny Cat, alongside private-label offerings.

2. Aon plc (NYSE:AON)

Short Percentage of Shares Outstanding: 1.40% 

On June 16, UBS lowered its price target on Aon plc (NYSE:AON) to $360 from $385 while maintaining a Neutral rating on the stock. The adjustment reflects the firm’s updated expectations for the company amid changing market conditions and a reassessment of the broader operating environment. While UBS continues to view the shares as fairly valued relative to their current risk-reward profile, the firm acknowledged Aon’s established position within the insurance brokerage industry and its ability to navigate evolving market dynamics. The revised target underscores a more measured outlook but does not materially alter the company’s long-term strategic positioning.

A day earlier, on June 15, Piper Sandler reduced its price target on Aon plc (NYSE:AON) to $355 from $360 while reiterating an Overweight rating on the shares. The firm identified Aon as its weekly focus idea, highlighting the company’s resilience despite the challenging conditions facing insurance brokers. According to Piper Sandler, Aon is not entirely immune to industry headwinds, but it is expected to outperform many competitors due to the strength and diversity of its business model. The firm further described Aon as an attractive defensive investment within the sector, citing its ability to generate stable results and adapt to changing market conditions.

Founded in 1982, Aon plc (NYSE:AON) is a leading professional services firm headquartered in Dublin, Ireland. The company provides a broad range of risk management, insurance, and reinsurance brokerage, and human capital consulting services to clients worldwide. In addition to its core offerings, Aon works with insurance providers to make customizable pet insurance solutions available, helping pet owners manage costs associated with accidents, illnesses, and routine veterinary care.

1. Lemonade, Inc. (NYSE:LMND)

Short Percentage of Shares Outstanding: 0.01% 

On June 11, Lemonade, Inc. (NYSE:LMND) announced that its renters’ insurance product is now available in Montana, further expanding the company’s geographic footprint in the United States. Management stated that the launch aligns with Lemonade’s mission of simplifying the insurance experience through technology-driven solutions, providing Montana residents with easier access to renters insurance through the company’s digital platform. The expansion reflects Lemonade’s continued efforts to grow its customer base and increase market penetration across additional states.

On June 8, TD Cowen raised its price target on Lemonade, Inc. (NYSE:LMND) to $55 from $33 while maintaining a Hold rating on the shares. The substantial increase in the target price reflects a more favorable outlook on the company’s prospects and suggests improved confidence in its operational performance and growth trajectory, even as the firm remains neutral on the stock.

Founded in 2015 and headquartered in New York, NY, Lemonade, Inc. (NYSE:LMND) is a digital insurance company that utilizes artificial intelligence and behavioral economics to replace traditional brokers and paperwork with seamless online apps and automated claims. The company also offers specialized pet health insurance policies that cover diagnostics, procedures, and medications for dogs and cats.

While we acknowledge the potential of LMND as a pet care stock to buy for consistent recurring revenue, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LMND and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 7 Best “Land Owner” Stocks to Buy for Hard Asset Value and Top 10 Stocks That Members of Congress Own.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.